Volume : 10, Issue : 03, March – 2023



Authors :

Abrar Saleh Alshehri

Abstract :

One of the biggest risk factors for the development of cardiovascular disease is hypercholesterolemia. Several major cardiovascular disorders are caused by atherosclerosis caused by hypercholesterolemia. Statins are widely regarded as the preferred medication for decreasing low-density lipoprotein (LDL) cholesterol, which minimizes the morbidity and mortality associated with coronary heart disease. Because statin treatment can cause muscle issues and other side effects, non-adherence and termination of statin therapy frequently results in poor control of plasma cholesterol levels and increased cardiovascular risk. The literature was reviewed and searched through databases such as PubMed and Embase, for all relevant articles that were published till the middle of 2022. Nevertheless, there is persuasive evidence that statin-treated patients still have significant residual cardiovascular risk. When taken with statin therapy, ezetimibe increases cholesterol-lowering efficacy and provides slight extra cardiovascular protection. Although having a better safety profile than statins, ezetimibe-induced cholesterol reduction is moderate when administered alone. As a result, there is an urgent need to identify alternative effective hypolipidemic medicines that can be administered in conjunction with statins or on their own if statins are not tolerated..

Cite This Article:

Please cite this article in press Abrar Saleh Alshehri, Roles Of Ezetimibe In Lipid Lowering And Preventing Cardiovascular Diseases.,Indo Am. J. P. Sci, 2023; 10(03).

Number of Downloads : 10


1. World Health Organization. Cardiovascular diseases. www.who.int/topics/cardiovascular_diseases/en/ (accessed 15 March 2022).
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics ‐ 2016 update: a report from the American Heart Association. Circulation 2016;133(4):e38‐e360.
3. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal 2014;35(42):2950‐9.
4. Rabar S, Harker M, O’Flynn N, Wierzbicki AS, Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356.
5. Wang DQ. Regulation of intestinal cholesterol absorption. Annu Rev Physiol. 2007;69:221–48.
6. Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol. 2011;73:239–59.
7. National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
8. Cholesterol Treatment Trialists, C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
9. Zhan S, Xia P, Tang M, Liu F, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events. Cochrane Database of Systematic Reviews 2017, Issue 1.
10. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient‐centered management of dyslipidemia: part 1‐ full report. Journal of Clinical Lipidology 2015;9(2):129‐69.
11. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia‐‐full report. Journal of Clinical Lipidology 2014;8(1):29‐60.
12. Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.
13. Keaney Jr JF, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3): 275–8.
14. Blazing MA et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVEIT study population. Am Heart J. 2014;168(2):205–12. e1.
15. Myocardial Infarction Genetics Consortium, I et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–82.
16. Hayek S et al. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol. 2013;111(4):532–9.
17. Morrone D et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–61.
18. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49(17):1753–62.
19. Davidson MH et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58(8):746–55.
20. McKenney JM et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94.
21. Holme I et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol. 2010;105(12):1802–8.
22. Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet. 2011;377(9784):2181–92.
23. Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13(1):159.